Clinical Trials
6 trialsNCT05283720 2026-06-02
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT06191744 2026-06-02
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT05201248 2025-01-07
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Genmab
Phase 1/2 Active not recruiting
NCT02371590 2018-02-23
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
Phase 2 Withdrawn